Impact of esomeprazole and vonoprazan on the antiplatelet effect of clopidogrel and prasugrel, with reference to CYP2C19 genotypes

Impact of esomeprazole and vonoprazan on the antiplatelet effect of clopidogrel and prasugrel, with reference to CYP2C19 genotypes - Impact of PPI on the antipratelet effect of P2Y12 inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019901

Enrollment

Registered

2015-11-24

Start date

2015-11-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease and upper gastrointestinal bleeding.

Interventions

(1) clopidgrel 75 mg once daily (qd) for 7 days. Subjecs receive six regimens in a crossover manner as (1) to (6). The order of six regimens is randomized. A clinical research coordinator (M. K.) m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy Japanese adult

Exclusion criteria

Exclusion criteria: Exclusion criteria are any underlying disease, smoking habit, past or present H. pylori infection, and habitual use of any medicine.

Design outcomes

Primary

Measure	Time frame
The primary outcome is antiplatelet effect with the six regimens as assessed by P2Y12 assay using Verify Now System (Accumetrics, Inc., San Diego, USA) on Day7 of each regimen.	—

Countries

Japan

Contacts

Public ContactTakahisa Furuta

Hamamatsu University School of Medicine Center for Clinical Research

furuta@hama-med.ac.jp053-435-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026